RCEL Revenue Jumps on Cohealyx Surge, Costs Fall: Is AVITA Medical Turning a Corner?
Solid Revenue Growth and Cost Control Lead First Quarter Headlines
AVITA Medical (NASDAQ: RCEL) opened 2026 with tangible progress: total revenue grew 4% year-over-year to $19.3 million, and operating expenses dropped 11% compared to Q1 2025. These shifts point to improving fundamentals—even as the company reported a net loss of $10.6 million, or $0.35 per share, that’s a noteworthy improvement versus last year’s $13.9 million net loss.
New Leadership and Product Expansion Support Strategic Reset
The appointment of Cary Vance as President and CEO, alongside a new Board Chair, caps a period of business stabilization. Recent launches—including RECELL GO versions, expanding clinical reimbursement for RECELL, and the growing impact of Cohealyx—are fueling fresh growth. Cohealyx, in particular, contributed significantly, supported by positive interim clinical data showing a ~20-day faster readiness for skin grafting versus standard approaches (mean time 13.6 vs. 33.2 days; p < 0.001).
Gross Margins Remain Strong Despite Product Mix Shift
Gross profit margin held at a healthy 81.7%, only slightly lower than last year. The margin reflects AVITA’s increasing mix of lower-margin products (Cohealyx and PermeaDerm, with average sales prices at 50% and 60% of RECELL, respectively). As shown in the table below, RECELL-only gross margin was even stronger at 85.0%:
| Product | Gross Margin (%) |
|---|---|
| Overall Portfolio | 81.7 |
| RECELL Only | 85.0 |
This margin resilience is a positive signal, particularly as management expects higher gross profit and stable operating expenses to gradually benefit operating profit, even if percent margins decline slightly as the portfolio expands.
Operating Efficiency and Cash Use Show Upward Trajectory
Operating expenses fell to $24.5 million (down $3.0 million year-over-year), led by cost discipline in sales, marketing, and R&D. Q1 cash use of $9.9 million was elevated by one-time and timing items, but management expects a turnaround in Q2 cash flow due to seasonal effects ending and stronger collections on late-quarter sales. The company ended the quarter with $14.3 million in cash and marketable securities, enough for near-term needs.
| Key Financials (Q1 2026) | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Total Revenue ($M) | 19.25 | 18.51 |
| Gross Profit ($M) | 15.73 | 15.68 |
| Gross Margin (%) | 81.7 | 84.7 |
| Total Operating Expenses ($M) | 24.53 | 27.51 |
| Net Loss ($M) | 10.61 | 13.86 |
| Cash & Marketable Securities ($M) | 14.26 | 17.85* |
*Previous year-end figure
BARDA Burns Deal Boosts Long-Term Outlook
AVITA’s 10-year, $25.5 million BARDA agreement adds recurring burn-preparedness revenue, further underpinning future results. Clearance for RECELL GO in Australia and New Zealand opens new lanes for commercialization abroad.
Full-Year Guidance Reaffirmed, with Eyes on Execution
Management is standing by its full-year 2026 revenue guidance of $80–85 million, implying 12–19% growth from 2025. Key drivers will be continued adoption of new products, stable reimbursement, and disciplined cash use.
Takeaway: Corner Turned, but Execution Matters
AVITA’s mix of revenue gains, higher product adoption, cost control, and margin resilience presents a more stable growth story for RCEL. Investors will watch Q2 cash trends and execution on expanded launches for proof that the company’s reset is sticking. For those researching RCEL, the evolving story hinges not just on growth, but on translating that growth into cash flow and, eventually, profitability.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI